1. Home
  2. Directory
  3. Massachusetts
  4. Boston
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1982923090

DR. HAVEN GARBER M.D.
Prescription History 1982923090
Internal Medicine in Boston, MA


Quality Rating: 81.38 out of 100 score

NPI Status: Active since May 28, 2010

Contact Information

1340 BOYLSTON ST
ANSIN BUILDING
BOSTON, MA
ZIP 02215
Phone: (617) 927-6000

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. HAVEN GARBER M.D., an active Internal Medicine specialist practicing in Boston, MA. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 175 documented patient claims. Among these therapy options, the most frequently utilized medication is Anastrozole, which accounts for 54 claims alone.

Medication Index

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 54
30-Day Fills 150.0
Days Supply 4,500
MA State Average Benchmarks
Peer Average Claims62.0
Peer Average 30-Day Fills152.9
Peer Average Days Supply4,549
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,770.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$32.78

State Avg Cost Per Claim

$26.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Ibrance

Generic Formulation: PalbociclibSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 15
30-Day Fills 18.6
Days Supply 532
MA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.9
Peer Average Days Supply694
Conservative Utilization

This provider writes prescriptions for this formulation 37.5% less frequently than the standard regional baseline metric for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $292,398.47 across this reporting matrix range.

Provider Avg Cost Per Claim

$19,493.23

State Avg Cost Per Claim

$14,837.02

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Palbociclib is used to treat a certain type of breast cancer. It works by slowing or stopping the growth of cancer cells.

Letrozole

Generic Formulation: LetrozoleSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 27
30-Day Fills 76.0
Days Supply 2,280
MA State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills130.0
Peer Average Days Supply3,862
Conservative Utilization

This provider writes prescriptions for this formulation 49.1% less frequently than the standard regional baseline metric for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,154.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$42.75

State Avg Cost Per Claim

$28.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 31
30-Day Fills 31.0
Days Supply 311
MA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.8
Peer Average Days Supply241
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 29.2% more claims than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $387.77 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.51

State Avg Cost Per Claim

$17.97

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Prochlorperazine Maleate

Generic Formulation: Prochlorperazine MaleateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 30
30-Day Fills 30.0
Days Supply 249
MA State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills25.9
Peer Average Days Supply330
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $285.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.51

State Avg Cost Per Claim

$17.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Therapeutic Applications

This medication is used to treat severe nausea and vomiting from certain causes (for example, after surgery or cancer treatment). Prochlorperazine belongs to a class of drugs known as phenothiazines. This medication is not recommended for use in children younger than 2 years or in children going through surgery.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 18
30-Day Fills 52.0
Days Supply 1,556
MA State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills84.9
Peer Average Days Supply2,528
Conservative Utilization

This provider writes prescriptions for this formulation 47.1% less frequently than the standard regional baseline metric for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $648.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$36.01

State Avg Cost Per Claim

$37.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. HAVEN GARBER M.D. provides transparency into local medical care patterns within Boston, MA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Internal Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.